« Under Iran's 'divinely ordained justice', girls as young as nine are charged with 'moral crimes'. The best that they can hope for is to die by hanging | Main | On "A View from the eye of the storm" »
December 21, 2004
NEJM early release correspondence regarding valdecoxib (Bextra)
Topics: Clinical Pharmacology20/12/2004. NEJM. (NEJM published early online on December 17, 2004)
As
a result of Pfizer's announcement that celecoxib has been shown to
increase the risk of MI, the NEJM has published a letter regarding
valdecoxib early. In it, the correspondents recommend that valdecoxib
should not be prescribed except in extraordinary circumstances. This
recommendation is based on the long delay between the initial evidence
of the cardiotoxicity of rofecoxib and its withdrawal, recent studies
demonstrating the cardiotoxicity of valdecoxib in high-risk patients,
the availability of other therapies not currently known to have
cardiovascular risks, and the lack of compelling evidence of
countervailing benefits. The correspondents state that they believe
this restriction should remain in effect until there are better safety
data for valdecoxib.
Read all of the NEJM article .....
Posted by Hyscience at December 21, 2004 3:30 AM
Articles Related to Clinical Pharmacology:
